NCT00543231View on ClinicalTrials.gov

A Phase I Study of G3139 Subcutaneous in Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

December 31, 2006

Conditions
Tumors
Interventions
DRUG

G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide

Trial Locations (1)

78229

Clinical Research Institute for Drug Development, San Antonio

Sponsors

Lead Sponsor

Genta Incorporated
All Listed Sponsors
lead

Genta Incorporated

INDUSTRY

NCT00543231 - A Phase I Study of G3139 Subcutaneous in Solid Tumors | Biotech Hunter | Biotech Hunter